Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
Nov 17, 2026, 14:10

Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?

Wolfgang Miesbach, Head of Hemostasis/Hemophilia Center at Medical Clinic 2 at University Hospital Frankfurt, shared a post on LinkedIn about a recent article by John W. Eikelboom, published in The New England Journal of Medicine, adding:

“One trial says yes. The other says not quite. Both are right.

Can aspirin alone prevent blood clots after hip or knee replacement? Two large trials in the same NEJM issue tested this, and John Eikelboom’s editorial puts them together.

  • EPCAT III (5,429 patients): aspirin from day 1 was as good as 5 days of rivaroxaban followed by aspirin. Clots were rare in both groups (0.48% vs 0.45%), and bleeding was similar. Almost all patients were at standard clot risk.
  • PEPPER (18,883 patients): 30 days of aspirin, warfarin or rivaroxaban. Aspirin could not be shown to be as effective as the anticoagulants (death or clot: 1.24% vs about 1%). But aspirin caused fewer bleeding and wound problems.
  • What this means: aspirin is a reasonable choice for many standard-risk patients. Anticoagulants prevent a few more clots but cause more bleeding. The higher the patient’s clot risk, the more the anticoagulant is worth it.
  • What is still missing: patients with a previous clot or active cancer were largely excluded from both trials.
    The question is no longer ‘does aspirin work?’ but ‘who needs more than aspirin?’ “

Title: Aspirin Therapy – Enough after Arthroplasty?

Authors: John W. Eikelboom

Wolfgang Miesbach: Aspirin vs Anticoagulants - Who Needs More Than Aspirin?

 

Stay updated with Hemostasis Today.